- Home
- DXC vs CRNX Comparison
DXC vs CRNX Comparison
Compare DXC & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- CRNX
- Stock Information
- Founded
- DXC 1959
- CRNX 2008
- Country
- DXC United States
- CRNX United States
- Employees
- DXC N/A
- CRNX N/A
- Industry
- DXC EDP Services
- CRNX Biotechnology: Pharmaceutical Preparations
- Sector
- DXC Technology
- CRNX Health Care
- Exchange
- DXC Nasdaq
- CRNX Nasdaq
- Market Cap
- DXC 2.6B
- CRNX 2.8B
- IPO Year
- DXC N/A
- CRNX 2018
- Fundamental
- Price
- DXC $13.60
- CRNX $41.19
- Analyst Decision
- DXC Hold
- CRNX Buy
- Analyst Count
- DXC 6
- CRNX 12
- Target Price
- DXC $15.60
- CRNX $74.45
- AVG Volume (30 Days)
- DXC 1.6M
- CRNX 1.6M
- Earning Date
- DXC 10-30-2025
- CRNX 11-06-2025
- Dividend Yield
- DXC N/A
- CRNX N/A
- EPS Growth
- DXC 384.35
- CRNX N/A
- EPS
- DXC 2.05
- CRNX N/A
- Revenue
- DXC $12,794,000,000.00
- CRNX $1,392,000.00
- Revenue This Year
- DXC N/A
- CRNX $428.87
- Revenue Next Year
- DXC N/A
- CRNX $958.11
- P/E Ratio
- DXC $6.62
- CRNX N/A
- Revenue Growth
- DXC N/A
- CRNX 0.51
- 52 Week Low
- DXC $12.24
- CRNX $24.10
- 52 Week High
- DXC $24.83
- CRNX $62.53
- Technical
- Relative Strength Index (RSI)
- DXC 51.57
- CRNX 52.52
- Support Level
- DXC $12.63
- CRNX $39.88
- Resistance Level
- DXC $13.46
- CRNX $43.09
- Average True Range (ATR)
- DXC 0.38
- CRNX 1.83
- MACD
- DXC 0.05
- CRNX -0.70
- Stochastic Oscillator
- DXC 90.69
- CRNX 23.18
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About CRNX Crinetics Pharmaceuticals Inc.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.